New shot could help control bleeding in severe hemophilia a

NCT ID NCT06703606

First seen Apr 03, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study tests a new medicine called marstacimab in people with severe hemophilia A who have been on another medicine (emicizumab) for at least 6 months. The goal is to see if switching to marstacimab is safe and how it works in the body. About 15 teens and adults aged 12 to 75 will receive weekly injections for 4 months. The results will help doctors guide patients who want to change their preventive treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ege University Faculty of Medicine Dean's Office

    RECRUITING

    Bornova, İzmir, 35100, Turkey (Türkiye)

  • K J Somaiya Hospital & Research Centre

    RECRUITING

    Mumbai, Maharashtra, 400022, India

  • Nirmal Hospital Pvt Ltd.

    RECRUITING

    Surat, Gujarat, 395002, India

  • Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center

    RECRUITING

    Los Angeles, California, 90007, United States

Conditions

Explore the condition pages connected to this study.